AYTU
Aytu BioPharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
EXXUA has shown early prescription and access traction, while the legacy portfolio provides some revenue base. If refill activity and commercial efficiency compound, the stock could rerate from its $2.15 anchor.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Complex warrant amendments and prior warrant-liability accounting create additional capital-structure and dilution uncertainty. [#SEC-8K-2026-04-02]
Momentum
100
Value
69
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.70 · Bull $4.00 · Bear $1.20
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.50
Why
Momentum100 · Δ7d -
Value69 · Δ7d -0.1
Sentiment62 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
100
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
69
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.2
Sentiment
62
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 99.5 / Value 68.9 / Sentiment 62.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$23.08M
Beta
0.37
Shares Out
10.73M
P/E (TTM)
15.7
P/S (TTM)
0.46
P/FCF (TTM) · Derived
6.23
Rev YoY
-32.7%
EPS YoY
-353.1%
Gross Margin
+60.1%
Op Margin
-13.2%
Net Debt
-$8.02M
Current Ratio
1.12
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology